Suppr超能文献

氯氮平增效策略。

Clozapine augmentation strategies.

作者信息

Roerig James L

出版信息

Ment Health Clin. 2019 Nov 27;9(6):336-348. doi: 10.9740/mhc.2019.11.336. eCollection 2019 Nov.

Abstract

Clozapine is established as the gold standard for antipsychotic treatment of patients suffering from treatment-resistant schizophrenia. Over virtually 3 decades, the level of inadequate response to clozapine was found to range from 40% to 60%. A heightened interest developed in the augmentation of clozapine to try to achieve response or maximize partial response. A large variety of drug groups have been investigated. This article focuses on the meta-analyses of these trials to discover reasonable evidence-based approaches to the management of patients not responding to clozapine.

摘要

氯氮平已被确立为治疗难治性精神分裂症患者抗精神病治疗的金标准。在近30年里,发现对氯氮平反应不足的比例在40%至60%之间。人们对增强氯氮平疗效以试图实现有效反应或使部分反应最大化的兴趣日益浓厚。已经对各种各样的药物组进行了研究。本文重点关注这些试验的荟萃分析,以发现合理的循证方法来管理对氯氮平无反应的患者。

相似文献

1
Clozapine augmentation strategies.氯氮平增效策略。
Ment Health Clin. 2019 Nov 27;9(6):336-348. doi: 10.9740/mhc.2019.11.336. eCollection 2019 Nov.
8
Schizophrenia: when clozapine fails.精神分裂症:氯氮平治疗失败时。
Curr Opin Psychiatry. 2015 May;28(3):243-8. doi: 10.1097/YCO.0000000000000159.
9
Clozapine resistance: augmentation strategies.氯氮平耐药:增效策略。
Eur Neuropsychopharmacol. 2012 Mar;22(3):165-82. doi: 10.1016/j.euroneuro.2011.08.005. Epub 2011 Sep 9.

引用本文的文献

9
Progress in Schizophrenia Research and Treatment.精神分裂症的研究与治疗进展
Focus (Am Psychiatr Publ). 2020 Oct;18(4):440-442. doi: 10.1176/appi.focus.18310. Epub 2020 Nov 5.

本文引用的文献

5
Pharmacological interventions for psychosis in Parkinson's disease patients.帕金森病患者精神病的药物干预。
Expert Opin Pharmacother. 2018 Apr;19(5):499-505. doi: 10.1080/14656566.2018.1445721. Epub 2018 Mar 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验